Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells

Oncogene

Volumn 28, Issue 33, 2009, Pages 2940-2947

  Sullivan, N J ^a,b   Sasser, A K ^a,b   Axel, A E ^b   Vesuna, F ^c   Raman, V ^c   Ramirez, N ^a,b   Oberyszyn, T M ^a,d   Hall, B M ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Epithelial mesenchymal transition; Interleukin 6; Metastasis; Tumor microenvironment

Indexed keywords

ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 6; NERVE CELL ADHESION MOLECULE; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER GRADING; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; EPITHELIUM CELL; HISTOLOGY; HUMAN; HUMAN CELL; MESENCHYME CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TUMOR; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MESODERM; MICE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PHENOTYPE; TRANSCRIPTION FACTORS; TWIST TRANSCRIPTION FACTOR; VIMENTIN;

GASTROPODA;

EID: 69249221254     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.180     Document Type: Article

References (36)

1. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. (2003). Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormonerefractory metastatic breast cancer patients. Br J Cancer 88: 1721-1726.
2. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. (2004). Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20.
3. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279.
4. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D et al. (2007). Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9: R15.
5. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M et al. (2008). Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283: 14665-14673.
6. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P et al. (2001). Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858.
7. Elston CW, Ellis IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
8. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19.
9. Heimann R, Hellman S. (2000). Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer 36: 1631-1639.
10. Jiang XP, Yang DC, Elliott RL, Head JF. (2000). Reduction in serum IL-6 after vacination of breast cancer patients with tumourassociated antigens is related to estrogen receptor status. Cytokine 12: 458-465.
11. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
12. Kishimoto T. (2006). Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8: S2.
13. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. (2003). Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48: 82-84.
14. Lebret SC, Newgreen DF, Thompson EW, Ackland ML. (2007). Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 9: R19. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980.
15. Massague J. (2008). TGFbeta in cancer. Cell 134: 215-230. Mironchik Y, Winnard Jr PT, Vesuna F, Kato Y, Wildes F, Pathak
16. AP et al. (2005). Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65: 10801-10809.
17. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ et al. (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197-209.
18. Naugler WE, Karin M. (2008). The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14: 109-119.
19. Nicolini A, Carpi A, Rossi G. (2006). Cytokines in breast cancer. Cytokine Growth Factor Rev 17: 325-337.
20. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T et al. (1993). Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53: 1696-1701.
21. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A et al. (2005). Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254.
22. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM. (2002). Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 87: 1281-1286.
23. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al. (2003). Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646.
24. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117: 3988-4002.
25. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno- Bueno G, Palacios J. (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
26. Sasser AK, Mundy BL, Smith KM, Studebaker AW, Axel AE, Haidet AM et al. (2007a). Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 254: 255-264.
27. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. (2007b). Interleukin-6 is a potent growth factor for ER-alphapositive human breast cancer. FASEB J 21: 3763-3770.
28. Singh A, Purohit A, Ghilchik MW, Reed MJ. (1999). The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6: 139-147.
29. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S et al. (2008). Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68: 9087-9095.
30. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
31. Thiery JP, Sleeman JP. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
32. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. (2006). Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174: 175-183.
33. van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L et al. (1993). Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 268: 15285- 15290.
34. Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T et al. (2006). ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 10: 227-239.
35. Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.
36. Zhang GJ, Adachi I. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427-1432.